Trials / Completed
CompletedNCT04585776
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
An Exploratory Study Assessing Time in Target Glucose Range Using a New Titration Scheme of LY900014 and Insulin Degludec in Patients With Type 1 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY900014 | Administered SC |
| DRUG | Insulin Degludec | Administered SC |
Timeline
- Start date
- 2020-10-30
- Primary completion
- 2021-05-27
- Completion
- 2021-05-27
- First posted
- 2020-10-14
- Last updated
- 2022-06-03
- Results posted
- 2022-06-03
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04585776. Inclusion in this directory is not an endorsement.